Figure 1.

Cumulative incidence of symptomatic (A) or RT-PCR-confirmed (symptomatic or asymptomatic; B) SARS-CoV-2 infections by study day

Population includes participants who were RT-PCR-negative for SARS-CoV-2 and seronegative at baseline. Infection was confirmed by central or local laboratory. After the 28-day efficacy assessment period, no scheduled SARS-CoV-2 RT-PCR testing was done (no surveillance testing during the follow-up period). Central laboratory RT-PCR (or local laboratory molecular testing) was done and reported if symptoms occurred or when participants had a local positive test for any reason. CAS + IMD=casirivimab and imdevimab.